Structured Self-Rated Response to Iontophoresis with Verapamil and Dexamethasone in Peyronie’s Disease

Table 1

Age at initial presentation, duration of symptoms, and clinical manifestations among responder and nonresponder men, expressed as mean (SD) for year and numbers (percent) for clinical manifestations.

Initial symptoms	Responder men	Nonresponder men	𝑃 value
Age; mean (SD)	57.96 (1.7)	59.00 (4.6)	0.705
Duration; mean (SD)	3.38 (0.3)	2.40 (0.3)	0.191
Curvature; 𝑁 (%)	17 (70.8)	5 (83.3)	0.954
Sudden onset deformity; 𝑁 (%)	11 (45.8)	4 (66.7)	0.651
Pain; 𝑁 (%)	5 (20.8)	2 (33.3)	0.603
Lump; 𝑁 (%)	3 (12.5)	1 (16.6)	0.481
ED; 𝑁 (%)	2 (8.3)	2 (33.3)	0.169
Shortening; 𝑁 (%)	23 (76.6)	2 (33.3)	0.003
Decreased sensation; 𝑁 (%)	4 (29.2)	0 (0.0)	0.557
Numbness; 𝑁 (%)	5 (20.8)	2 (33.3)	0.603
Painful sensation; 𝑁 (%)	3 (12.5)	1 (16.7)	0.481

Bold refers to significant results.